Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine

Urology. 1996 May;47(5):777-81; discussion 781. doi: 10.1016/s0090-4295(96)00027-1.

Abstract

Objectives: Priapism is a common and currently unsatisfactorily managed complication of sickle cell disease (SCD). In June 1994, 6 SCD patients received a new therapeutic regimen to prevent the occurrence and recurrence of priapism.

Methods: The patients (5 with SS and 1 with SC) were adults and had frequent episodes of stuttering priapism (SP), and two of them had had acute episodes (AP) lasting more than 3 hours. The treatment consists of preventive oral administration of the alpha-adrenergic agent etilefrine, and self-administered intracavernous injection (SICI) of the same agent to reverse episodes lasting more than 1 hour.

Results: Since the beginning of treatment, all patients were protected against AP, 4 patients had no recurrence with the oral treatment alone, 2 had to use SICI, 1 occasionally and 1 constantly. There was no modification of sexual activity and no complications. Blood pressure was unaffected.

Conclusions: This treatment is simple, cheap, and self-administered. It should be proposed to all patients with SCD in all geographic areas as part of an educational program for active prevention of this severe complication.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adrenergic alpha-Agonists / administration & dosage*
  • Adult
  • Anemia, Sickle Cell / complications
  • Etilefrine / administration & dosage*
  • Humans
  • Injections
  • Male
  • Penis
  • Priapism / etiology
  • Priapism / prevention & control*
  • Self Administration

Substances

  • Adrenergic alpha-Agonists
  • Etilefrine